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Abstract
Background: With improved access to pediatric antiretroviral therapy (ART) in resource-limited settings, more children
could experience first-line ART treatment failure.
Methods: We performed a retrospective cohort analysis using electronic medical records from HIV-infected children who
initiated ART at McCord Hospital’s Sinikithemba Clinic in KwaZulu-Natal, South Africa, from August 2003 to December 2010.
We analyzed all records from children who began second-line ART due to first-line treatment failure. We used logistic
regression to compare viral outcomes in Protease Inhibitor (PI)-based versus Non-Nucleoside Reverse Transcriptase Inhibitor
(NNRTI)-based second-line ART, controlling for time on first-line ART, sex, and whether HIV genotyping guided the regimen
change.
Results: Of the 880 children who initiated ART during this time period, 80 (9.1%) switched to second-line ART due to
therapeutic failure of first-line ART after a median of 95 weeks (IQR 65–147 weeks). Eight (10%) of the failures received
NNRTI-based second-line ART, all of whom failed a PI-based first-line regimen. Seventy (87.5%) received PI-based second-
line ART, all of whom failed a NNRTI-based first-line regimen. Two children (2.5%) received non-standard dual therapy as
second-line ART. Six months after switching ART regimens, the viral suppression rate was significantly higher in the PI group
(82%) than in the NNRTI group (29%; p=0.003). Forty-one children (51%) were tested for genotypic resistance prior to
switching to second-line ART. There was no significant difference in six month viral suppression (p=0.38) between children
with and without genotype testing. Conclusion: NNRTI-based second-line ART carries a high risk of virologic failure
compared to PI-based second-line ART.
Citation: Zanoni BC, Sunpath H, Feeney ME (2012) Pediatric Response to Second-Line Antiretroviral Therapy in South Africa. PLoS ONE 7(11): e49591. doi:10.1371/
journal.pone.0049591
Editor: Nicolas Sluis-Cremer, University of Pittsburgh, United States of America
Received September 4, 2012; Accepted October 12, 2012; Published November 20, 2012
Copyright:  2012 Zanoni et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was generously supported by the Sullivan Family Foundation and the Elizabeth Glaser Pediatric AIDS Foundation (M.E.F.). M.E.F. is the
recipient of the Jewelers for Children Elizabeth Glaser Scientist Award. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: margaret.feeney@ucsf.edu
Introduction
Since 2005, there has been a dramatic increase in ART access
for HIV-infected children in sub-Saharan Africa [1,2,3]. However,
the availability of adequate care and treatment programs remain
limited [4] and most treatment programs in developing countries
have a restricted formulary of antiretroviral medications, partic-
ularly for children. Resistance to first-line ART is an increasing
problem [5,6,7,8]. With the limited treatment options available,
choosing the correct second-line therapy is critical [4,9,10], yet
resistance testing is not available in most resource-limited settings.
Increasing use of single-dose nevirapine (NVP) in Prevention of
Mother to Child Transmission (PMTCT) programs could limit the
effectiveness of non-nucleoside reverse transcriptase inhibitors
(NNRTI) in younger children [11,12]. Archived resistance
mutations in the NVP-exposed infants could potentially limit both
first- and second-line use of NNRTI in resource-limited settings
[10,13].
We performed a retrospective cohort study to evaluate the
response to second-line ART in children in South Africa by
comparing NNRTI-based second-line ART with PI-based second-
line ART. In addition, we used existing resistance data to compare
outcomes between children receiving standard second-line ART
and those whose regimen change was guided by resistance testing.
Materials and Methods
Ethics Statement
The protocol was approved by McCord Hospital’s Research
Ethics Committee and the Partners Human Research Committee.
All patients and their adult caregivers accessing care at McCord
Hospital signed a written consent to have their medical
information stored on an electronic medical record database used
for clinical and research purposes.
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We performed a retrospective cohort study using electronic
medical records from HIV-infected pediatric patients (#18 years
old) who initiated antiretroviral therapy at McCord Hospital’s
Sinikithemba Clinic in KwaZulu-Natal, South Africa, from August
2003 to December 2010. We analyzed all records from children
who changed their regimen from first-line ART. We recorded
clinical and demographic information at baseline prior to ART
initiation and collected six monthly CD4, viral load, weight, and
ALT, and hemoglobin to evaluate the response to second-line
ART.
Study population and standard of care
McCord Hospital is a semi-private, urban hospital providing
care for a mostly Zulu-speaking population in Durban, South
Africa. We followed patients in the study from the time they
initiated ART until they died, transferred care to another facility,
were lost to follow-up, or until the study end date of December 31,
2010. During the study period, children initiated ART when their
HIV disease reached World Health Organization (WHO) stage 3
or 4 and/or their CD4 percentage was less than 20% in children
younger than 18 months, or less than 15% in children older than
18 months, in accordance with South African National Treatment
Guidelines [14]. Based on national guidelines in South Africa,
children less than 3 years of age received a PI-based first-line
treatment regimen comprised of lopinavir/ritonavir, stavudine,
and lamivudine [14]. Children older than 3 years initiated an
NNRTI-based treatment regimen comprised of efaverinez,
stavudine, and lamivudine [14]. According to local guidelines,
routine laboratory monitoring included baseline CD4 and six
monthly CD4 and viral loads [14]. The South African National
Treatment Guidelines define virologic failure as two consecutive
viral loads greater than 1,000 copies/ml after six months of ART,
despite adherence, with viral loads separated by three months
[15]. Children failing an NNRTI-based regimen were changed to
standard second-line ART of zidovudine (AZT), didanosine (DDI),
and lopinavir/ritonavir. Children failing a PI-based regimen
received AZT, DDI, and efaverinez.
Resistance Testing
Resistance testing was performed from January 1, 2005 to
August 15, 2006 for consecutive children ,18 years with a viral
load .1,000 copies/ml under a separate research protocol.
Genotyping of plasma virus was performed using the TRU-
GENEH HIV-1 Genotyping Test on an OpenGeneH DNA
Sequencing System (Bayer HealthCare Diagnostics, Berkeley,
CA) as directed by the manufacturer. Confirmatory HIV-1 RNA
testing using the NucliSens EasyQ HIV-1 (bioMeriux diagnostics,
Marcy l’Etoille, France) was performed for specimens with either
initial results of ,10,000 copies/mL or if viral RNA could not be
amplified for sequencing. Substitutions at the following positions
were considered major drug resistance mutations: for reverse
transcriptase (RT), M41L, K65R, D67N, insertion 69, K70R,
L74V, L100I, K103N, V106A/M, V108I, Q151M, Y181C,
M184V, Y188C/L, G190A, L210W, T215Y/F, K219Q/E/N/
R, P225H, and M230L; for protease (PR), D30N, V32I, L33F/I,
M46I/L, I47V/A, G48V, I50V, V82A/T/F/S, I84V, and L90M.
During this study period, clinicians used results of the resistance
testing to guide choice in NRTI backbone; however, national
guidelines dictated choice of PI or NNRTI.
Data Collection
We evaluated medical records from patients aged #18 years old
who changed ART regimens at McCord Hospital’s Sinikithemba
Clinic from August 2003 to December 2010. TrackCare Software
was used to maintain electronic medical records. All records were
cross referenced with paper charts. Collected data included age at
ART initiation, gender, ART regimens, presence of tuberculosis
(TB) and non-TB opportunistic infections, chronic diarrhea
(longer than 14 days), baseline and six monthly laboratory results
including absolute and CD4 percentage, viral load and hemoglo-
bin. At the time of ART regimen change, we recorded whether or
not the children had resistance testing performed and whether
they had major resistance mutations. We also recorded the
presence of chronic diarrhea and opportunistic infections based on
documentation in the electronic medical record as well as review
of paper records. If these conditions were not documented in the
electronic medical record or paper charts, we reported them as
absent.
Statistical Analysis
We conducted statistical analyses using SAS statistical software
(Release 9.2, Carey, NC). We first determined univariate
associations between nine demographic and clinical covariates,
which, based upon clinical observations and prior studies, were
hypothesized as potentially important correlates of response to
second-line ART. We then performed multivariate logistic
regression controlling for age, sex, ART regimen, and presence
of resistance testing.
Results
Between August 2003 and December 2010, 880 children
initiated ART at McCord Hospital’s Sinikithemba Clinic. Of
these children, 186 (21%) changed ART from their initial regimen
prior to December 31, 2010. Of those, 80 (9.1%) were due to
virologic failure and 106 (12%) were due to toxicity, intolerance,
or a change in national guidelines. Risk factors for first-line
virologic failure among children in this cohort were previously
reported [16]. Of those who switched to second-line ART due to
virologic failure, 70 (87.5%) failed NNRTI-based first-line ART,
eight (10%) failed PI-based first-line ART and two (2.5%) failed
non-standard dual therapy. Clinical and demographic character-
istics for this cohort are located in Table 1. The median time to
ART failure in this cohort was 95 weeks (interquartile rage (IQR)
65–147 weeks). There was no difference in time to failure between
those who failed NNRTI-based first-line and PI-based first-line
(median 93 vs. 107 weeks, respectively; p=0.36). Children who
failed a PI-based first-line regimen were younger (p=0.0006), had
higher absolute CD4 counts (p=0.005) but not percentages, and
had a greater increase in absolute CD4 from baseline prior to the
time of regimen change compared to those who failed NNRTI-
based first-line (p=0.012).
Response to second-line ART
Six months after regimen change, virologic suppression was
80% (53 of 66) in the PI-based second-line group and 25% (2 of 8)
in the NNRTI-based second-line group (p=0.009). We performed
univariate logistic regression to determine correlates of viral
suppression six months after changing to second-line ART
(Table 2). We found that females (p=0.025) and children taking
NNRTI-based second-line therapy (p=0.0093) had significantly
worse viral suppression rates at six months. Using multivariate
logistic regression, controlling for age, sex, first-line treatment
regimen and resistance testing (Table 3), we found that children
Pediatric Second-Line Antiretroviral Therapy
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suppression six months after changing ART regimen compared to
those on an NNRTI-based second-line [95% CI 2.7–232.7;
p=0.015]. In addition, females were more likely to experience
virologic failure six months after initiating second-line ART [95%
CI 1.4–25.3; p=0.005]. Age (p=0.56) and resistance testing
(p=0.22) were not significantly associated with viral suppression
rate, as indicated in Table 3.
Resistance testing
In this cohort, 41 consecutive children received antiretroviral
resistance testing prior to changing to second-line ART under a
separate research protocol for children failing first-line ART.
Among children who required a change to second-line ART, there
was no significant difference in baseline treatment regimen
between those who received testing or those who did not; 34
(83%) received NNRTI-based first-line treatment and six (15%)
received PI-based first-line treatment (p=0.16). Resistance testing
was performed on one child receiving non-standard dual therapy.
Additionally, there was no difference in age, sex, CD4 count at
time of regimen change, viral load prior to regimen change, or
time from ART initiation to regimen change between those who
received resistance testing and those who did not (Table 1). The
rate of viral suppression 6 months after regimen change was
similar among those with resistance testing (61%) and without
resistance testing (79%) (p=0.11). Of the children who failed to
achieve viral suppression six months after switching to NNRTI-
based second-line therapy, all (100%) had NNRTI resistance
mutations even though they did not receive NNRTI first-line
therapy. Of the two (25%) children who did achieve viral
suppression on NNRTI-based second-line ART, both had only
PI and NRTI class mutations. Only one (4%) child who failed
NNRTI-based first-line ART had minor PI mutations while four
(67%) children who failed first-line PI regimens had major NNRTI
mutations.
Discussion
Sub-Saharan Africa continues to carry the burden of new HIV
infections. More than 70% of all new HIV infections occur in the
region [1], and fewer than half of all HIV-infected pregnant
women in sub-Saharan Africa receive an intervention to prevent
HIV transmission to their children [1]. However, there has been a
dramatic increase in the availability of antiretroviral therapy for
children in sub-Saharan Africa since 2005 [1]. This increased
access to first-line ART in children means that, over time, more
Table 1. Baseline Clinical and Demographics Characteristics of A Cohort of HIV-Infected Children Failing 1
st Line ART in Durban,
South Africa Stratified by Initial Treatment Regimen and Presence of Resistance Testing.
Covariate NNRTI regimen PI regimen p-value
Resistance testing
available
Resistance
testing not done p-value
N=70 N=8 N=41 N=39
Median Age at initiation (years) 6.8 [3.7–9.5] 1.2 [1.0–2.1] 0.0006 5.8 [2.6–8.0] 6.6 [2.5–9.7] 0.51
Females 31 (44%) 2 (25%) 0.3 17 (41%) 18 (46%) 0.68
Cd4 Median (cells/mL) 421 [273–663] 883 [450–1238] 0.005 441 [303–735] 434 [280–630] 0.59
CD4 percent 18.1 [12–25] 23 [16–28] 0.36 19 [13–25] 19 [13–26] 0.51
Change in CD4 from baseline 189 [34–392] 685 [70–881] 0.012 190 [43–417] 180 [54–485] 0.49
Change in CD4% from baseline 7.7 [1.8–14.1] 8.9 [4.3–24.6] 0.42 7.2 [2–14] 10 [2.5–17] 0.31
Weeks on ART 93 [66–155] 107 [64–113] 0.36 87 [63–132] 95 [67–168] 0.36
Viral load at change 10,200 [3,760–51,000] 49,000 [6,400–84,000] 0.7 16,000 [6,300–55,000] 6800 [1,900–75,300] 0.19
Resistance Testing 34 (49%) 6 (75%) 0.16
NNRTI based 1
st line 34 (85%) 36 (95%) 0.16
doi:10.1371/journal.pone.0049591.t001
Table 2. Univariate Analysis: Predictors of Six Month Viral
Suppression After Change to Second-Line ART in a Cohort of
HIV-Infected Children Failing 1
st Line ART in Durban, South
Africa.
Odds Ratio [95% CI] P value
Age at initiation (years) 0.99 [0.87–1.14] 0.9453
Females 3.60 [1.17–11.06] 0.0253
Cd4 Median (cells/mL) 1.00 [0.99–1.00] 0.6550
CD4 percent 0.96 [0.90–1.03] 0.2391
Change in CD4 from baseline 1.00 [0.99–1.00] 0.5965
Change in CD4% from baseline 0.96 [0.91–1.02] 0.1932
Weeks on ART 1.00 [0.99–1.01] 0.8033
NNRTI 1
st line 0.10 [0.02–0.56] 0.0093
Log Viral load at change 0.96 [0.72–1.28] 0.7652
Resistance testing 2.48 [0.82–7.55] 0.1096
doi:10.1371/journal.pone.0049591.t002
Table 3. Multivariate Analysis: Predictors of Six Month Viral
Suppression After Change to Second-Line ART in a Cohort of
HIV-Infected Children Failing 1
st line ART in Durban, South
Africa.
Odds Ratio [95% CI] P value
Age at initiation (years) 1.05 [0.89–1.25] 0.5564
Females 5.99 [1.42–25.34] 0.0150
NNRTI 1
st line 0.04 [0.004–0.37] 0.0047
Resistance testing 2.17 [0.63–7.62] 0.2196
doi:10.1371/journal.pone.0049591.t003
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particularly in poorly monitored or rural clinics [17,18]. Unfor-
tunately, in many resource-limited settings, access to second-line
pediatric ART is challenging and options are very limited [19].
In South Africa, children less than 3 years of age weighing less
than 10 Kg initiate a PI-based ART regimen containing
lopinavir/ritonavir due to exposure to single dose nevirapine
(NVP) through PMTCT programs [15]. IMPAACT P1060
demonstrated lopinavir/ritonavir’s superiority in efficacy and
safety to NVP as first-line treatment in PMTCT exposed and
unexposed children [12,20]. Although lopinavir/ritonavir has a
relatively high genetic barrier to the development of resistance
[21,22], its effectiveness is limited by poor palatability, metabolic
complications [23], and drug-drug interactions [24,25]. In a high-
burden tuberculosis area, the interaction between lopinavir/
ritonavir and rifampicin can lead to sub-therapeutic drug levels
and virologic failure [16,26]. In resource-limited settings, when
these children fail first-line PI-based ART, they are limited to
NNRTI-based second-line regimens.
We have shown that, in our cohort, NNRTI-based second-line
ART was not an optimal choice since 75% of children failed this
regimen. It is possible that archived NNRTI resistance due to
single dose NVP exposure led to this failure; however, since this
was a retrospective study, we were unable to accurately assess
exposure to single-dose NVP. Studies have found that up to 19%
of women exposed to single dose NVP carry resistant mutations
[27]. These mutations could be transmitted to their children
through failed PMTCT or transmitted to subsequent children.
HIVNET 012 indicated that 46% of children who fail PMTCT
carry NVP resistance mutations [27], indicating high-level
NNRTI resistance occurs in areas using single-dose NVP-based
PMTCT strategies. Other studies have demonstrated even higher
levels of transmitted resistance in failed PMTCT regimens [13].
The Nevirapine Resistance Study (NEVEREST) evaluated
whether prior exposure to single dose nevirapine would affect
outcomes in children who initially achieved viral suppression with
a lopinavir/ritonavir-containing first-line regimen. The study
indicated that children who initially achieved viral suppression
but switched to a nevirapine-containing first-line regimen had 10
times higher risk of developing viremia .1000 copies/ml
compared to those that remained on lopinavir/ritonavir-contain-
ing first-line ART [11]. In anticipation of increasing pediatric first-
line PI failures, data from PENPACT-1 suggest that children
failing PI-based first-line ART could delay switching to second-line
ART given the low risk for selecting additional NRTI and PI
mutations [28]. Given the limited second-line options for these
children, delaying regimen change would seem reasonable.
However, there remains an urgent need for increased access to
more pediatric formulations of ART in resource-limited settings.
Otherwise, children failing first-line PI regimens will have
extremely limited second-line options.
In resource-limited settings, HIV resistance testing is not widely
available due to expense. Currently, South Africa has a low
prevalence (,5%) of transmitted PI resistance in children [5].
However, transmitted NNRTI resistance in children is classified as
intermediate (5–15%) due to single-dose NVP exposure through
PMTCT [5]. This severely limits available ART regimens for
children. Given the intermediate level of transmitted NNRTI
resistance and evidence of inferior viral suppression when used as
first or second-line ART, this currently leaves limited options for
children in South Africa after they fail PI-based first- or second-
line therapy. Although Darunavir and Tipranavir have shown
promising efficacy with limited toxicity in treatment-experienced
children with significant PI resistance mutations, unfortunately
these agents are not widely accessible to children in South Africa
or other resource-limited settings at this time [19,29,30].
In this setting, females were significantly less likely to reach viral
suppression after six months of second-line ART compared to
males. Gender differences in mortality [31,32], baseline CD4
[32,33] and baseline viral load [32,33,34] have been seen in
African pediatric HIV cohorts. Behavioral, socioeconomic, genet-
ic, and hormonal risk factors could contribute to the differential
responses to infectious diseases between males and females.
This study has several limitations. First, it was a retrospective
study; therefore, we relied on previously captured data. We were
unable to reliably assess adherence or identify children who were
exposed to single-dose NVP through PMTCT. This could limit
the generalizability of this study to other resource-limited settings.
In addition, there were a relatively low number of children who
failed first-line PI-based therapy, thereby limiting the power of the
study.
Conclusion
In settings of high NNRTI use for prevention of perinatal
transmission of HIV, the use of NNRTI-based second-line ART
after failure of a boosted PI-containing first-line regimen may
result in poor virologic outcomes. Since children who develop
rebound viremia on boosted PI first-line regimens are slow to
develop major PI resistance mutations, these children may still
achieve viral suppression with improved adherence. Improvement
of current boosted PI pediatric formulations, such as co-
formulated sprinkles that could improve adherence and palatabil-
ity, are necessary. Newer agents or classes of ART with improved
toxicity profiles, palatability and decreased drug interactions are
needed in resource-limited settings.
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